Clinical trial
TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian…
NCT00022347 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00022347 |
|---|---|
| Title | TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
| Official title | A Phase II Study of TLK 286 in Platinum Resistant Advanced Epithelial Ovarian Cancer |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer |
| Intervention type | Drug |
| Interventions | canfosfamide hydrochloride |
| Start date | May 1, 2001 |
| Primary completion | Apr 1, 2004 |
| Completion | Dec 1, 2009 |
| First posted | Jan 14, 2004 |
| Last update posted | Jun 26, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: